| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002113A1 Vitamin c compositions |
| 01/09/2003 | WO2003002060A2 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2002099026A8 Methods and formulations for enhancing the dissolution of a solid material in liquid |
| 01/09/2003 | WO2002076376A3 A stable pharmaceutical composition of pravastatin |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002069994A3 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002036093A3 Anti-adiposis composition based on garlic bulb extracts |
| 01/09/2003 | WO2002026997A3 Dsp-16 dual-specificity phosphatase |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001081376A3 Apo-ai/aii peptide derivatives |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001068637A3 Method for the preparation of tetrahydrobenzothiepines |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009777 Using galanin agonist in the generation of medicament for the treatment of nerve damage |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008907 Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008899 For use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex |
| 01/09/2003 | US20030008892 Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| 01/09/2003 | US20030008890 For therapy of neurological and psychological disorders |
| 01/09/2003 | US20030008886 For therapy of pain |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008879 For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety |
| 01/09/2003 | US20030008876 Can mimic or block the effect of extracellular calcium on a cell surface calcium receptor; for use in therapy |
| 01/09/2003 | US20030008874 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008869 Combination of a PTPase inhibitor and a sulfonylurea agent |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008859 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/09/2003 | US20030008843 Bulking agents as satiety agents |
| 01/09/2003 | US20030008836 Eukaryotic gene expression cassette and uses thereof |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008810 Nutritional intervention composition for enhancing and extending satiety |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008354 Peptide for use in the diagnosis and treatment of parkinson's, cancer and developmental defects |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008058 Containing fruit juice of prickly pear cactus |
| 01/09/2003 | US20030008025 Composition for inhibiting increase of blood sugar level or lowering blood sugar level |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008016 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 01/09/2003 | US20030008002 Containing titanium dioxide platelets |
| 01/09/2003 | US20030007988 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (PNP) |
| 01/09/2003 | US20030007969 Administering integrin antagonist |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007963 Treatment of pompe's disease |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2489681A1 Aryl boronic acids for treating obesity |
| 01/09/2003 | CA2487857A1 Aryl boronate functionalized polymers for treating obesity |
| 01/09/2003 | CA2455654A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451163A1 Agent for preventing or treating organ functional disorders and order dysfunction |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451037A1 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2449486A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2420548A1 Composition comprising vitamin c and a pyrone or furanone compound |
| 01/09/2003 | CA2419888A1 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273657A1 Novel protein, process for producing the same and use thereof |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273307A1 Preparations for preventing bile acid diarrhea |
| 01/08/2003 | EP1273294A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process |
| 01/08/2003 | EP1273293A1 Fenofibrate suspension in a hydrophilic polymer solution |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272852A1 Tpst-assay for diagnosis of autism and related disorders |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272643A1 Talaromyces emersonii beta-glucanases |
| 01/08/2003 | EP1272637A1 A METHOD FOR SCREENING FOR AUTOIMMUNE DISEASE BY IDENTIFYING POLYMORPHISMS IN IL-12 p40 |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272616A2 Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |
| 01/08/2003 | EP1272516A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272487A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |